1 / 41

Good Clinical Practice

Good Clinical Practice. A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International gclasby@promedica-intl.com 714-799-1617 x 25. GCP What It Is.

oshin
Télécharger la présentation

Good Clinical Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Good Clinical Practice A Review for OCRA US RAC Study GroupSeptember 2005Ginger Clasby, MS Promedica Internationalgclasby@promedica-intl.com 714-799-1617 x 25

  2. GCPWhat It Is • An international ethical & scientific quality standard for designing, conducting, recording & reporting human clinical studies • EU • Japan • US • Applies to registration studies that may have an impact on safety & welfare of human subjects

  3. GCPParticipating Parties • IRB/Ethics Committee • Investigators • Sponsor • Regulatory Authorities

  4. GCPKey Documents • Investigator Brochure • Study Protocol • Informed Consent Document

  5. GCPPrinciples • Studies in accordance with Declaration of Helsinki; consistent with GCP & applicable regulatory requirements • Studies initiated & continued only if anticipated benefits outweigh risks • Rights, safety & welfare of human subjects take priority over interests of science & society • Available non-clinical & clinical info on product adequate to support study

  6. GCPPrinciples • Studies scientifically sound; described in clear, detailed protocol • Study in compliance with IRB/EC approved protocol • Medical care given to subjects is the responsibility of qualified medical professional(s) • Individuals conducting studies qualified by education, training & experience • Freely given informed consent obtained from every subject prior to study participation

  7. GCPPrinciples • Study information recorded, handled & stored to allow accurate reporting, interpretation & verification • Confidentiality of subject records protected in accordance with applicable regulatory requirements • Investigational products manufactured, handled & stored in accordance with GCP & used in accordance with approved protocol • Systems/procedures implemented to assure quality of study

  8. IRB/ECRoles & Responsibilities To safeguard study subjects’ rights & welfare by: • Evaluation/disposition of study proposal • Evaluation of proposed subject consent materials • Evaluation of emergency use consent methodology • Evaluation of investigator qualifications • Ongoing review of study progress (at least yearly) • Evaluation of proposed subject compensation plans

  9. IRB/ECComposition & Operations • Membership has qualifications & experience to evaluate science, medical aspects & ethics of proposed study • ≥ 5 members • ≥ 1 member whose primary interest in nonscientific • ≥ 1 member independent of institution or study site • Written SOPs & records • Decisions rendered at announced meetings with quorum in attendance

  10. IRB/ECComposition & Operations • Only members participating in review should vote • Investigator may provide info on study, but should not be involved in review or vote • Nonmembers with expertise in special areas may be invited to assist with review (but cannot vote)

  11. IRB/ECProcedures • Document group membership & qualifications • Schedule meetings & notify members • Conduct initial & ongoing review of studies • Determine ongoing review frequency • Provide expedited review of minor study changes, in accordance with regulatory requirements • Specify that no subject should be enrolled in study prior to IRB/EC approval

  12. IRB/ECProcedures • Specify that no deviations from protocol should be initiated without prior IRB/EC approval • Emergency situations require immediate notification of IRB/EC after the fact • Specify that Investigator should promptly report: • Protocol deviations • Changes increasing subject risk or study procedures • Serious and unexpected adverse events

  13. IRB/ECProcedures • Notify Investigator promptly of: • Study-related decisions • Reason for decisions • Procedures for appeal of decisions

  14. IRB/ECRequired Records • Relevant records maintained ≥ 3 yr after study completion • Records available for review by regulatory authorities

  15. IRB/ECWhat is Reviewed • Investigator Brochure or Report of Prior Investigations • Study protocol & amendments • Investigator qualifications • Informed consent documents, including subject recruiting tools • Other written information provided to subjects • Subject compensation plans • Adverse events • Protocol deviations

  16. IRB/ECWhen Reviews Occur • Prior to study initiation at site • At least yearly during study • During study, as necessitated by: • Changes in protocol, consent documents, etc. • Changes in study investigator • Reports of serious or unanticipated device-related adverse events • At study completion or termination

  17. InvestigatorRoles & Responsibilities • Qualified to conduct study • Have adequate resources to conduct study • Provide medical care to study subjects • Regular communication with IRB/EC reviewing study • Compliance with study protocol • Maintenance of investigational product accountability • Compliance with study randomization & unmasking procedures • Provide informed consent to study subjects

  18. Investigator ResponsibilitiesAppropriate Qualifications • Training & experience demonstrated via: • Medical license • CV • Specialized study training • GCP training • If study responsibilities delegated, need a list of qualified persons to whom responsibilities are delegated

  19. Investigator ResponsibilitiesAdequate Resources • Suitable staff & good methods for keeping them apprised • Suitable facilities • Appropriate patient population • Access to disease or condition • Volume of patients with disease or condition

  20. Investigator ResponsibilitiesMedical Care • Make medical decisions regarding patient treatment • Adequate care for study-related adverse events • Diligence in ascertaining reason(s) for subject withdrawals from study

  21. Investigator ResponsibilitiesIRB/EC Communications • IRB/EC approval prior to study initiation • IRB/EC kept apprised of events & progress during study

  22. Investigator ResponsibilitiesProtocol Compliance • Conduct study in accordance with protocol • May not deviate from protocol without Sponsor/IRB approval • Document deviations from protocol

  23. Investigator ResponsibilitiesInvestigational Product Accountability • Maintain accountability at study site • Document product receipt & disposition • Maintain product in a secure area • Use product only in accordance with protocol • Disallow use of product by anyone not registered with study

  24. Investigator ResponsibilitiesRandomization Procedures & Unmasking • Follow study randomization procedures • Unmask only in accordance with protocol • Document noncompliance or premature unmasking

  25. Investigator ResponsibilitiesSubject Informed Consent • Comply with regulatory requirements • Update consent documents as necessary • Inform subject that study involves “investigational” product • May not coerce subject to participate • May not waive subject’s legal rights • Keep subject informed of new information regarding study

  26. Investigator ResponsibilitiesSubject Informed Consent • Provide informed consent in understandable language • Give subject the chance to ask questions • If subject can’t read, need impartial witness • If subject is “disadvantaged”, need legally authorized witness • Get subject consent in writing prior to initiation of study procedures • Give subject a copy of signed consent document

  27. Investigator ResponsibilitiesRequired Records & Reports • Essential regulatory document file(s) • Protocol & amendments • Approved informed consent documents • Product accountability documentation • Investigator qualifications & agreements • IRB correspondence • Study delegation list • Subject screening/enrollment logs • Study monitoring reports • Calibration/maintenance logs • Memos to file

  28. Investigator ResponsibilitiesRequired Records & Reports • Source documentation • Data capture forms (study-specific) • Data clarification forms • Fully executed informed consent documents

  29. Investigator ResponsibilitiesRequired Records & Reports • Written periodic status reports to IRB/EC • Written reports of protocol deviations to Sponsor & IRB/EC • Serious or unanticipated product-related adverse events to Sponsor & IRB/EC • Notification of study suspension or termination to IRB/EC • Final study report to IRB/EC • Retain ≥ 2 yr

  30. SponsorRoles & Responsibilities • Study quality assurance • Appropriately qualified medical personnel to advise on study • Utilization of qualified personnel in study design & operations • Study management, data handling & record keeping • Investigator selection & training • Definition/allocation of study responsibilities

  31. SponsorRoles & Responsibilities • Facilitation of communications between Investigators • Study compensation (investigators and/or subjects) & financing • Regulatory authority notification/submission • Confirmation of IRB/EC review/approval • Investigational product information • Investigational product manufacturing, packaging, labeling & coding • Investigational product supply & handling

  32. SponsorRoles & Responsibilities • Record access • Ongoing safety evaluation & reporting • Serious/unanticipated adverse event reporting • Study monitoring • Study noncompliance procedures • Study termination or suspension notification • Study reports

  33. SponsorRoles & Responsibilities • Sponsor may transfer responsibilities to CRO • Transfer must be documented in writing • Sponsor still has ultimate responsibility for study quality and data integrity

  34. Study ProtocolComponents • General administrative info • Background • Study purpose & objectives • Study design • Subject eligibility requirements • How subjects will be treated • How safety & efficacy will be assessed • Sample size justification & statistical analysis methods

  35. Study ProtocolComponents • How data will be captured & maintained • Monitoring procedures • Proposed informed consent document

  36. Informed Consent DocumentComponents • Statement that study involves “research” & product “experimental” (if applicable) • Study purpose • Number of expected study subjects to be enrolled • Study treatment(s) & probability for random assignment • Study exams & procedures for duration of trial • Subject’s responsibilities • Foreseeable risks to subject (embryo, fetus, nursing infant)

  37. Informed Consent DocumentComponents • Expected benefits • Alternatives procedures or therapies & associated risk/benefit • Compensation available in event of study-related injury or sickness • Anticipated payments to subject for study participation • Anticipated expenses to subject for study participation • Statement that participation is voluntary

  38. Informed Consent DocumentComponents • Description of extent to which confidentiality can be assured • Commitment to keep subject apprised on new information that may affect subject’s willingness to participate in study • Contact info for questions re: subject rights; trial-related adverse events • Circumstances under which subject’s participation may be terminated

  39. Investigator BrochureWhat It Is A compilation of clinical & non-clinical data on the product that is relevant to the product’s study in humans Necessary for Investigator & IRB/EC review to assess the risks/benefits associated with study

  40. Investigator BrochureComponents Product formulation summary Introduction/background info regarding product & investigational plan • Investigational product physical, chemical & pharmaceutical properties & formulation • Non-clinical studies • Human clinical studies • Summary of data & guidance for Investigator

  41. Good Clinical PracticeReference Documents & Links • ICH - E6: Guideline for Good Clinical Practice • 21 CFR 50 - Informed Consent • 21 CFR 56 - Institutional Review Board • http://www.ich.org/cache/compo/276-254-1.html • http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm

More Related